Retour aux projets

18018.2 PFLS-LS

Preclinical development of a new drug for cognitive disorders including Alzheimer¿s disease

Résumé

Preclinical development of a new drug for cognitive disorders including Alzheimer¿s disease

Textes supplémentaires

Abstract

The CTI project 13875.1 PFLS-LS lead to the discovery of compounds HiQ0013 specific for the á7 neuronal nicotinic acetylcholine receptor and HiQ0025 which is specific for the á3â2|subtype. HiQ0013 a partial agonist at á7 enhances the response to acetylcholine at concentration in the nanomolar range. HiQ0013 was found to be active in rodents and in aged monkeys. The aim of this project is to complete preclinical testing and to consolidate data obtained at backup candidates.

Participants

Daniel Bertrand

Wirtschaftspartner

daniel.bertrand@hiqscreen.com

HiQScreen SàRL Daniel Bertrand Route de Compois 6 1222 Vésenaz GE CH

Jean-Louis Reymond

Kontaktperson

reymond@ioc.unibe.ch

Universität Bern Department of Chemistry and Biochem Jean-Louis Reymond Freiestrasse 3 3012 Bern BE CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2016-04-30
Date de fin
2018-04-30
Coûts totaux approuvés
CHF 190000.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%